Re-understanding of the mechanism of coagulation disorder in liver cirrhosis

Rongrong SUN; Na HE; Fenna ZHANG; Xinyi ZHANG; Ziyi WANG; Hui WANG; Nana BIAN; Honglin YAN

doi:10.12449/JCH240330

Volume 40 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(3): 616-620

PDF( 622 KB)

Re-understanding of the mechanism of coagulation disorder in liver cirrhosis

DOI: 10.12449/JCH240330

1.
Department of Gastroenterology，The First Affiliated Hospital of Xi’an Medical College，Xi’an 710077，China
2.
Graduate School of Xi’an Medical University，Xi’an 710021，China

Research funding:

Shaanxi Provincial Education Science “13th Five-Year Plan” Project (SGH20Y1330);

Youan Specialist Medical Alliance for Liver and Infectious Diseases Special Fund (LM202003);

Shaanxi Institute of Basic Science （Chemistry and Biology） 2022 Basic Science Research Programme Projects (22JHQ09)

More Information

Corresponding author: YAN Honglin， yanhonglin666@163.com （ORCID： 0009-0003-3060-7348）
Received Date: 2023-07-16
Accepted Date: 2023-08-14
Published Date: 2024-03-20

Abstract

Abstract

The liver plays an important regulatory role in maintaining the dynamic balance of coagulation and anticoagulation in the body. Such dynamic balance is fragile in patients with liver cirrhosis， and the risk of bleeding can be increased due to reductions in coagulation factors and platelet count and excessive fibrinolysis； meanwhile， thrombus can be formed due to the increases in von Willebrand factor and coagulation factor Ⅷ， the reductions in anticoagulant protein C and anticoagulant protein S， the increase in thrombin-generating potential， and alterations in antifibrinolytic components. This article reviews the mechanisms of coagulation disorder in liver cirrhosis， so as to help clinicians with the prevention and treatment of bleeding or thrombotic disorders in patients with liver cirrhosis.
- Liver Cirrhosis,
- Blood Coagulation,
- Haemorrhage,
- Thrombosis

FullText(HTML)

References(34)

References

[1]	JIANG H, LI Y, SHENG Q, et al. Relationship between hepatitis B virus infection and platelet production and dysfunction[J]. Platelets, 2022, 33( 2): 212- 218. DOI: 10.1080/09537104.2021.2002836.
[2]	DAHAL S, UPADHYAY S, BANJADE R, et al. Thrombocytopenia in patients with chronic hepatitis C virus infection[J]. Mediterr J Hematol Infect Dis, 2017, 9( 1): e2017019. DOI: 10.4084/MJHID.2017.019.
[3]	SILCZUK A, HABRAT B. Alcohol-induced thrombocytopenia: Current review[J]. Alcohol, 2020, 86: 9- 16. DOI: 10.1016/j.alcohol.2020.02.166.
[4]	BASILI S, RAPARELLI V, NAPOLEONE L, et al. Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER study[J]. Am J Gastroenterol, 2018, 113( 3): 368- 375. DOI: 10.1038/ajg.2017.457.
[5]	ZANETTO A, CAMPELLO E, BULATO C, et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death[J]. J Hepatol, 2022, 77( 3): 660- 669. DOI: 10.1016/j.jhep.2022.03.009.
[6]	BASILI S, RAPARELLI V, RIGGIO O, et al. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation[J]. Liver Int, 2011, 31( 10): 1533- 1540. DOI: 10.1111/j.1478-3231.2011.02617.x.
[7]	EGAN K, DILLON A, DUNNE E, et al. Increased soluble GPVI levels in cirrhosis: evidence for early in vivo platelet activation[J]. J Thromb Thrombolysis, 2017, 43( 1): 54- 59. DOI: 10.1007/s11239-016-1401-0.
[8]	MATSUI T, USUI M, WADA H, et al. Platelet activation assessed by glycoprotein vi/platelet ratio is associated with portal vein thrombosis after hepatectomy and splenectomy in patients with liver cirrhosis[J]. Clin Appl Thromb Hemost, 2018, 24( 2): 254- 262. DOI: 10.1177/1076029617725600.
[9]	CHEN SH, TSAI SC, LU HC. Platelets as a gauge of liver disease kinetics?[J]. Int J Mol Sci, 2022, 23( 19). DOI: 10.3390/ijms231911460.
[10]	TRIPODI A, PRIMIGNANI M, CHANTARANGKUL V, et al. An imbalance of pro-vs anti-coagulation factors in plasma from patients with cirrhosis[J]. Gastroenterology, 2009, 137( 6): 2105- 2111. DOI: 10.1053/j.gastro.2009.08.045.
[11]	POOTHONG J, POTTEKAT A, SIIRIN M, et al. Factor Ⅷ exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum[J]. Blood, 2020, 135( 21): 1899- 1911. DOI: 10.1182/blood.2019002867.
[12]	ZHANG K, WANG S, MALHOTRA J, et al. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis[J]. EMBO J, 2011, 30( 7): 1357- 1375. DOI: 10.1038/emboj.2011.52.
[13]	SINEGRE T, DURON C, LECOMPTE T, et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis[J]. J Thromb Haemost, 2018, 16( 6): 1132- 1140. DOI: 10.1111/jth.14011.
[14]	TRIPODI A, PRIMIGNANI M, LEMMA L, et al. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis[J]. J Hepatol, 2013, 59( 2): 265- 270. DOI: 10.1016/j.jhep.2013.03.036.
[15]	SCHEINER B, BALCAR L, NUSSBAUMER RJ, et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD[J]. J Hepatol, 2022, 76( 5): 1090- 1099. DOI: 10.1016/j.jhep.2021.12.038.
[16]	BOS S, van den BOOM B, KAMPHUISEN PW, et al. Haemostatic profiles are similar across all aetiologies of cirrhosis[J]. Thromb Haemost, 2019, 119( 2): 246- 253. DOI: 10.1055/s-0038-1676954.
[17]	TRIPODI A, PRIMIGNANI M, LEMMA L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method[J]. Hepatology, 2010, 52( 1): 249- 255. DOI: 10.1002/hep.23653.
[18]	TAKAYA H, NAMISAKI T, ASADA S, et al. ADAMTS13, VWF, and endotoxin are interrelated and associated with the severity of liver cirrhosis via hypercoagulability[J]. J Clin Med, 2022, 11( 7): 1835. DOI: 10.3390/jcm11071835.
[19]	PÉPIN M, KLEINJAN A, HAJAGE D, et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer[J]. J Thromb Haemost, 2016, 14( 2): 306- 315. DOI: 10.1111/jth.13205.
[20]	ZERMATTEN MG, FRAGA M, MORADPOUR D, et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis[J]. Hepatology, 2020, 71( 6): 2135- 2148. DOI: 10.1002/hep.31201.
[21]	KUME Y, IKEDA H, INOUE M, et al. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats[J]. FEBS Lett, 2007, 581( 8): 1631- 1634. DOI: 10.1016/j.febslet.2007.03.029.
[22]	NIIYA M, UEMURA M, ZHENG XW, et al. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo[J]. J Thromb Haemost, 2006, 4( 5): 1063- 1070. DOI: 10.1111/j.1538-7836.2006.01893.x.
[23]	MANNUCCI PM, CAPOFERRI C, CANCIANI MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease[J]. Br J Haematol, 2004, 126( 2): 213- 218. DOI: 10.1111/j.1365-2141.2004.05009.x.
[24]	LISMAN T, BONGERS TN, ADELMEIJER J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity[J]. Hepatology, 2006, 44( 1): 53- 61. DOI: 10.1002/hep.21231.
[25]	SENZOLO M, COPPELL J, CHOLONGITAS E, et al. The effects of glycosaminoglycans on coagulation: a thromboelastographic study[J]. Blood Coagul Fibrinolysis, 2007, 18( 3): 227- 236. DOI: 10.1097/MBC.0b013e328010bd3d.
[26]	TRIPODI A. Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin[J]. Thromb Haemost, 2017, 117( 5): 830- 836. DOI: 10.1160/TH16-10-0806.
[27]	KREMERS R, KLEINEGRIS MC, NINIVAGGI M, et al. Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis[J]. PLoS One, 2017, 12( 5): e0177020. DOI: 10.1371/journal.pone.0177020.
[28]	WAN J, ROBERTS LN, HENDRIX W, et al. Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay[J]. J Thromb Haemost, 2020, 18( 4): 834- 843. DOI: 10.1111/jth.14751.
[29]	von MEIJENFELDT FA, LISMAN T. Fibrinolysis in patients with liver disease[J]. Semin Thromb Hemost, 2021, 47( 5): 601- 609. DOI: 10.1055/s-0040-1718924.
[30]	RIJKEN DC, KOCK EL, GUIMARãES AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests[J]. J Thromb Haemost, 2012, 10( 10): 2116- 2122. DOI: 10.1111/j.1538-7836.2012.04901.x.
[31]	PUNTER M, VOS BE, MULDER BM, et al. Poroelasticity of(bio)polymer networks during compression: theory and experiment[J]. Soft Matter, 2020, 16( 5): 1298- 1305. DOI: 10.1039/c9sm01973a.
[32]	DRIEVER EG, LISMAN T. Fibrin clot properties and thrombus composition in cirrhosis[J]. Res Pract Thromb Haemost, 2023, 7( 1): 100055. DOI: 10.1016/j.rpth.2023.100055.
[33]	HUGENHOLTZ GC, MACRAE F, ADELMEIJER J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen[J]. J Thromb Haemost, 2016, 14( 5): 1054- 1066. DOI: 10.1111/jth.13278.
[34]	MARTINEZ J, MACDONALD KA, PALASCAK JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains[J]. Blood, 1983, 61( 6): 1196- 1202.

Relative Articles

[1]	Min XU, Yu NI, Rui ZHANG, Xiaobing WANG, Yuan HUANG. Advances in minimally invasive treatment of upper gastrointestinal bleeding in liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 424-431. doi: 10.3969/j.issn.1001-5256.2023.02.028
[2]	Qingjuan HE, Yingxia FANG, Xuchen LIU, Zhongbin LI. Risk factors for rebleeding after emergency esophageal variceal ligation in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1801-1805. doi: 10.3969/j.issn.1001-5256.2022.08.016
[3]	Yuhang YIN, Wentao XU, Fuliang HE, Xingshun QI. An excerpt of EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis(2022)[J]. Journal of Clinical Hepatology, 2022, 38(6): 1252-1255. doi: 10.3969/j.issn.1001-5256.2022.06.008
[4]	Wentao XU, Yue YIN, Yiling LI, Xingshun QI. An excerpt of vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2021, 37(5): 1042-1044. doi: 10.3969/j.issn.1001-5256.2021.05.013
[5]	Jiali MA, Yu JIANG, Julong HU, Zhenglin AI, Lingling HE, Yuling ZHOU, Xiuxia LIANG, Yijun LIN, Hongshan WEI, Ping LI. Risk factors for rebleeding after endoscopic selective variceal devascularization in patients with hepatitis B cirrhosis and acute variceal bleeding[J]. Journal of Clinical Hepatology, 2021, 37(11): 2569-2574. doi: 10.3969/j.issn.1001-5256.2021.11.017
[6]	Yingying CAO, Tao HAN, Yu ZHANG, Fang LIU, Jing LIANG, Haixia YUAN, Jun LI, Huiling XIANG. Rebleeding and prognosis of patients with liver cirrhosis and severe esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2021, 37(6): 1326-1330. doi: 10.3969/j.issn.1001-5256.2021.06.022
[7]	Yan ZHANG, Huiguo DING. Risk factors for early rebleeding after endoscopic therapy for esophageal varices in cirrhotic patients[J]. Journal of Clinical Hepatology, 2021, 37(9): 2087-2091. doi: 10.3969/j.issn.1001-5256.2021.09.017
[8]	Chen XU, Miao JIANG. Value of platelet-albumin-bilirubin score in predicting the short-term prognosis of patients with liver cirrhosis and acute upper gastrointestinal bleeding[J]. Journal of Clinical Hepatology, 2021, 37(7): 1578-1581. doi: 10.3969/j.issn.1001-5256.2021.07.020
[9]	Decui PEI, Sisi WEN, Haichun HU, Xiuxia ZHENG, Linfei LI, Jiewen DENG. Role of thromboelastography in assessing the risk of spontaneous bleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(7): 1582-1588. doi: 10.3969/j.issn.1001-5256.2021.07.021
[10]	Ying XU, Xiaoping HUANG, Li CHEN, Wei SUN, Yan WANG, Jianhe GAN. Role of coagulation abnormalities in thrombosis in patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(3): 560-564. doi: 10.3969/j.issn.1001-5256.2021.03.012
[11]	Ma JiaLi, Chen Xu, He LingLing, Wei HongShan, Li Ping. Value of Child-Pugh score,Model for End-Stage Liver Disease score,MELD combined with serum sodium concentration,APASAL score,and R-score in predicting rebleeding and death in cirrhotic patients with esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2020, 36(6): 1278-1283. doi: 10.3969/j.issn.1001-5256.2020.06.018
[12]	Xiong Zhuang, Liu YangYang, Huo ShaoKai, Gong JiaLian, Jin TianYi, Wang Qiang, Wang HuiLin, Liu TieJun, Leng Yan. Research advances in vitamin K1 in treatment of coagulopathy of liver failure[J]. Journal of Clinical Hepatology, 2019, 35(9): 2099-2103. doi: 10.3969/j.issn.1001-5256.2019.09.048
[13]	Hong Cen, Han JuQiang, Qi XingShun. An excerpt of AGA clinical practice update: Coagulation in cirrhosis (2019)[J]. Journal of Clinical Hepatology, 2019, 35(10): 2191-2191. doi: 10.3969/j.issn.1001-5256.2019.10.011
[14]	Ma JiaLi, Li Ping, Wei HongShan, Zhou YuLing, Liang XiuXia, Hu JuLong, Ai ZhengLin, Chen Xu. Risk factors for glue extrusion bleeding after endoscopic therapy for esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2018, 34(1): 89-91. doi: 10.3969/j.issn.1001-5256.2018.01.018
[15]	He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041
[16]	Zhang LiHang, Wang ShanJuan, Lu LunGen, Liu YanLi, Wang YiFei, Xie JinBi. Predictive value of coagulation test parameters for acute upper gastrointestinal bleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2130-2135. doi: 10.3969/j.issn.1001-5256.2018.10.014
[17]	Xing WenLi, Li Qian. Thromboprophylaxis and bleeding control in patients with liver disease in the intensive care unit[J]. Journal of Clinical Hepatology, 2018, 34(10): 2237-2240. doi: 10.3969/j.issn.1001-5256.2018.10.039
[18]	Deng Han, Qi XingShun, Guo XiaoZhong. UK guidelines on the management of variceal haemorrhage in cirrhotic patients (2015): an excerpt of recommendations[J]. Journal of Clinical Hepatology, 2015, 31(6): 852-854. doi: 10.3969/j.issn.1001-5256.2015.06.007
[19]	Lu XiaoMin, Wang ZhenNing, Yang Jun. Significance of molecular markers of prethrombotic state in monitoring portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 404-406. doi: 10.3969/j.issn.1001-5256.2015.03.022

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 林仕高，杨苗苗，伍大华，谢乐. 基于“肝主凝血”分析收敛法防治出血性疾病. 中医药导报. 2025(01): 164-168 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1204) PDF downloads(121)

Re-understanding of the mechanism of coagulation disorder in liver cirrhosis

DOI: 10.12449/JCH240330

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Re-understanding of the mechanism of coagulation disorder in liver cirrhosis

DOI: 10.12449/JCH240330

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content